QURE vs. PBYI, GBIO, FHTX, GTHX, TSVT, OMER, PYXS, ALDX, OVID, and ELYM
Should you be buying uniQure stock or one of its competitors? The main competitors of uniQure include Puma Biotechnology (PBYI), Generation Bio (GBIO), Foghorn Therapeutics (FHTX), G1 Therapeutics (GTHX), 2seventy bio (TSVT), Omeros (OMER), Pyxis Oncology (PYXS), Aldeyra Therapeutics (ALDX), Ovid Therapeutics (OVID), and Eliem Therapeutics (ELYM). These companies are all part of the "pharmaceutical preparations" industry.
Puma Biotechnology (NASDAQ:PBYI) and uniQure (NASDAQ:QURE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, community ranking, media sentiment, earnings, dividends and profitability.
uniQure received 101 more outperform votes than Puma Biotechnology when rated by MarketBeat users. Likewise, 70.70% of users gave uniQure an outperform vote while only 66.50% of users gave Puma Biotechnology an outperform vote.
Puma Biotechnology has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, uniQure has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500.
In the previous week, uniQure had 4 more articles in the media than Puma Biotechnology. MarketBeat recorded 4 mentions for uniQure and 0 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.32 beat uniQure's score of 0.00 indicating that uniQure is being referred to more favorably in the news media.
Puma Biotechnology presently has a consensus target price of $7.00, suggesting a potential upside of 70.94%. uniQure has a consensus target price of $24.75, suggesting a potential upside of 394.01%. Given Puma Biotechnology's higher possible upside, analysts clearly believe uniQure is more favorable than Puma Biotechnology.
Puma Biotechnology has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.
61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 78.8% of uniQure shares are owned by institutional investors. 22.7% of Puma Biotechnology shares are owned by company insiders. Comparatively, 4.7% of uniQure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Puma Biotechnology has a net margin of 6.79% compared to Puma Biotechnology's net margin of -1,562.22%. uniQure's return on equity of 35.49% beat Puma Biotechnology's return on equity.
Summary
Puma Biotechnology beats uniQure on 10 of the 18 factors compared between the two stocks.
Get uniQure News Delivered to You Automatically
Sign up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QURE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
